Topic

Oxbryta (voxelotor)

A collection of 28 issues

Getting Oxbryta (Voxelotor) Coverage from Blue Cross Blue Shield in Ohio: Post-FDA Withdrawal Guide to Alternative Therapies

Answer Box: Oxbryta Coverage in Ohio (2024-2025) Oxbryta (voxelotor) was voluntarily withdrawn from the U.S. market in September 2024 due to safety concerns, and Blue Cross Blue Shield plans in Ohio now automatically deny coverage. Your fastest path forward: 1) Schedule an urgent appointment with your hematologist to discuss

Getting Oxbryta (Voxelotor) Covered by Blue Cross Blue Shield California: Complete Guide to Appeals After FDA Withdrawal

Answer Box: Oxbryta Coverage After FDA Withdrawal Oxbryta (voxelotor) was withdrawn from the U.S. market in November 2024, making new coverage requests extremely challenging. However, patients currently stable on Oxbryta may appeal denials through Blue Shield of California's internal process, then California's Independent Medical Review

Oxbryta (Voxelotor) Denied by UnitedHealthcare in Michigan? FDA Withdrawal & Alternative Coverage Options

Answer Box: Oxbryta Coverage Status & Next Steps Oxbryta (voxelotor) is no longer available in the US after Pfizer's voluntary withdrawal in September 2024 due to safety concerns. UnitedHealthcare automatically denies all Oxbryta claims since the drug lost FDA approval. If you're currently taking Oxbryta, work

Oxbryta (Voxelotor) Coverage Denial by Humana in Virginia: Understanding FDA Withdrawal and Alternative Treatment Appeals

Answer Box: Oxbryta Coverage Status in Virginia Oxbryta (voxelotor) is no longer available in the United States as of September 2024 due to FDA withdrawal following safety concerns. Humana and all insurers now automatically deny coverage because the drug lost FDA approval. If you're currently on Oxbryta or

Oxbryta (Voxelotor) Coverage with Humana in North Carolina: What You Need to Know After FDA Withdrawal

Answer Box: Oxbryta (Voxelotor) Coverage Status Oxbryta (voxelotor) is no longer available in the United States. Pfizer voluntarily withdrew the medication from all global markets on September 25-26, 2024, following FDA safety alerts. Humana and other insurers now deny all claims due to loss of FDA approval. If you'

Oxbryta (Voxelotor) Coverage by UnitedHealthcare in Illinois: FDA Withdrawal Impact and Alternative Treatment Appeals

Answer Box: Oxbryta Coverage Status Oxbryta (voxelotor) was voluntarily withdrawn from the U.S. market in September 2024 due to safety concerns, including increased vaso-occlusive crises and deaths. UnitedHealthcare and all U.S. insurers now deny Oxbryta claims because the drug is no longer available or FDA-approved. If you need

Oxbryta (Voxelotor) Coverage with UnitedHealthcare in Virginia: FDA Withdrawal Impact and Alternative Options

Answer Box: Oxbryta Coverage Status with UnitedHealthcare in Virginia Important: Oxbryta (voxelotor) was voluntarily withdrawn from the U.S. market by Pfizer in September 2024 following FDA review. UnitedHealthcare now typically denies claims due to loss of FDA approval. If you're currently taking Oxbryta, work with your hematologist

UnitedHealthcare Coverage for Oxbryta (Voxelotor) in Washington: 2024 FDA Withdrawal and Alternative Options

Answer Box: Oxbryta Coverage Status Oxbryta (voxelotor) is no longer available and cannot be covered by UnitedHealthcare or any insurer. Pfizer voluntarily withdrew the drug in September 2024 following FDA safety review. Your fastest path forward: Work with your hematologist to transition to FDA-approved alternatives like hydroxyurea, L-glutamine, or crizanlizumab.

Myths vs. Facts: Getting Oxbryta (Voxelotor) Covered by Aetna in Illinois - What Patients Need to Know

Answer Box: Oxbryta Coverage Reality in Illinois Critical Update: Oxbryta (voxelotor) was voluntarily withdrawn from the U.S. market by Pfizer in September 2024 due to safety concerns. Claims are now denied due to loss of FDA approval. Illinois patients with sickle cell disease should work with their healthcare providers

If Oxbryta (Voxelotor) Isn't Approved by Blue Cross Blue Shield in Michigan: Formulary Alternatives & Exception Paths

Answer Box: Oxbryta (Voxelotor) Status Update Oxbryta (voxelotor) was withdrawn from the U.S. market in September 2024 by Pfizer following FDA's request based on post-marketing studies showing potential harm despite hemoglobin improvements. Blue Cross Blue Shield of Michigan now denies Oxbryta claims due to loss of FDA